

---

## Product Data Sheet

---

Product Name: JLK 6  
Cat. No.: GC13619

### Chemical Properties

Cas. No. 62252-26-0

Chemical Name 7-amino-4-chloro-3-methoxy-1H-isochromen-1-one

SMILES COC1=C(Cl)C2=CC=C(N)C=C2C(O1)=O

Formula  $C_{10}H_8ClNO_3$  M.Wt 225.63

Solubility <22.56mg/ml in DMSO; <5.64mg/ml in ethanol Storage Store at RT

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

JLK 6, an isocoumarin, is a selective inhibitor of  $\gamma$ -secretase, with an IC<sub>50</sub> value between 10  $\mu$ M-1 mM [1, 2].

The enzyme  $\gamma$ -secretase catalyzes the cleavage of  $\beta$ -Amyloid precursor protein ( $\beta$ APP) to produce Amyloid  $\beta$ -peptide ( $A\beta$ ).  $A\beta$  is a part of the plaque present in the brain of patients with Alzheimer's disease.  $\gamma$ -secretase also targets other substrates like Notch. Notch is a transmembrane protein which is involved in important functions during different stages in development, both embryonic and adulthood [1].

HEK293 cells were used. In these cells, wild-type  $\beta$ APP was overexpressed (962 fmol/mL in 35-mm wells). JLK6 markedly reduced  $A\beta$  secreted from these cells. Interestingly, JLK6 potentiated the recovery of two fragments. Immunological characterization indicated that one fragment was labelled with a specific antibody against the Asp1 residue of  $A\beta$ . JLK6 also inhibited the  $A\beta$  recovery from cells overexpressing Swedish-mutant  $\beta$ APP to a similar extent [2].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

In the zebrafish embryo, JLK isocoumarin inhibitors did not change the Notch pathway responsible for somitogenesis. Unlike other  $\gamma$ -secretase inhibitors, these agents did not affect E-cadherin processing. JLKs did not inhibit  $\alpha$ -secretase,  $\beta$ -site APP cleaving enzymes (BACE) 1 and BACE2, GSK3 $\beta$  kinase and proteasome. JLK inhibitors prevented A $\beta$  production without inducing unwanted cleavages of other proteins [1].

### References:

- [1]. Petit A, Pasini A, Alves Da Costa C, et al. JLK isocoumarin inhibitors: Selective  $\gamma$ -secretase inhibitors that do not interfere with notch pathway in vitro or in vivo. *Journal of neuroscience research*, 2003, 74(3): 370-377.
- [2]. Petit A, Bihel F, da Costa CA, et al. New protease inhibitors prevent  $\gamma$ -secretase-mediated production of A $\beta$ 40/42 without affecting Notch cleavage. *Nature cell biology*, 2001, 3(5): 507-511.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA